NSF Prevention in clinical practice: Summary of recommendations and guidelines in the United States, Canada, and Europe

Journal of Magnetic Resonance Imaging

Volumn 30, Issue 6, 2009, Pages 1357-1363

  Leiner, Tim ^a   Kucharczyk, Walter ^b  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Contrast media; Gadolinium chelates; Guidelines; MRI; Nephrogenic systemic fibrosis (prevention of)

Indexed keywords

CREATININE; GADOBENATE DIMEGLUMINE; GADOBUTROL; GADODIAMIDE; GADOFOSVESET; GADOLINIUM; GADOLINIUM PENTETATE; GADOTERATE MEGLUMINE; GADOTERIDOL; GADOVERSETAMIDE; GADOXETIC ACID;

ACUTE KIDNEY FAILURE; CANADA; CLINICAL ASSESSMENT; CONFERENCE PAPER; CREATININE BLOOD LEVEL; DIALYSIS; DRUG CONTRAINDICATION; DRUG EXCRETION; DRUG EXPOSURE; DRUG INFORMATION; EUROPE; FOOD AND DRUG ADMINISTRATION; GLOMERULUS FILTRATION RATE; HEALTH CARE PERSONNEL; HEMODIALYSIS; HIGH RISK PATIENT; INCIDENCE; KIDNEY FAILURE; KIDNEY FUNCTION; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSTETRIC PATIENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; RADIATION DOSE; RADIOLOGY; RENAL PROTECTION; RISK ASSESSMENT; RISK FACTOR; UNITED STATES;

CANADA; CONTRAST MEDIA; DOSE-RESPONSE RELATIONSHIP, DRUG; EUROPE; GADOLINIUM; HUMANS; KIDNEY FAILURE; MAGNETIC RESONANCE IMAGING; NEPHROGENIC FIBROSING DERMOPATHY; PRACTICE GUIDELINES AS TOPIC; UNITED STATES;

EID: 73649090430     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.22021     Document Type: Conference Paper

References (5)

1. Miki Y, Isoda H, Togashi K. Guideline to use gadolinium-based contrast agents at Kyoto University Hospital. J Magn Reson Imaging 2009;30:1364-1365.
2. American College of Radiology (ACR). Manual on Contrast Media, 6.0 edition. American College of Radiology; 2008:54-56. (www.acr.org/ SecondaryMainMenuCategories/quality-safety/contrast-manual.aspx)
3. United States Food and Drug Administration. Information for Healthcare Professionals Gadolinium-Based Contrast Agents for Magnetic Resonance Imaging (marketed as Magnevist, MultiHance, Omniscan, OptiMARK, ProHance). Washington, D.C. (accessed October 7, 2009) http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm142884.htm
4. Padilla-Thornton A, Rafat Zand K, Barrett B, Stein L, Andrew G, Forster BB. Canadian Association of Radiologists National Advisory on Gadolinium Administration and Nephrogenic Systemic Fibrosis. CARJ 2008;59:237-240.
5. European Society of Urogenital Radiology. ESUR guideline: gadolinium-based contrast media and nephrogenic systemic fibrosis. Vienna, Austria (accessed October 7, 2009) http://www.esur.org/Nephrogenic-Fibrosis.39. 0.html